2019-nCoV Spike RBD



Protein Name 2019-nCoV Spike RBD
Catalog Number 19Cov-S12019Cov-S120
Purity 95% or above
Protein Construction A DNA sequence encoding the SARS-CoV-2 (2019 nCoV) spike protein receptor binding domain (Arg319-Phe541)
Endotoxin <0.1 EU per ug of protein as determined by LAL method
Origin Species Coronavirus (2019-nCoV) isolate Wuhan-Hu-1
Expression Host HEK293F
Protein type Recombinant
Purification tag C-terminal 6xHis-tag
Molecule Mass Predicted molecular weight 24.7 kD.
Formulation PBS
Regulation restrictions For research use only
Shipping Recombinant proteins are provided as frozen liquid and will be shipped out with dry ice.
Stability and storage The protein is stable in a liquid state at -70℃ for 12 months. Avoid repeated freeze-thaw cycles.

Additional information


100µg, 1mg

Background information

The SARS-CoV-2 (2019-nCoV) Spike RBD (receptor binding domain) has been identified as the key viral element allowing the virus docking to the target cells. RDB is recognized by the ACE2 surface membrane receptor [1-3]. RBD is a candidate for subunit prophylactic vaccines against SARS-CoVs [4, 5]. RBD is also at the center of therapeutic approaches, such as the development and testing of small peptide inhibitors or soluble ACE2 to block the SARS-CoV-2 entry into target cells [6].


  1. Li F., 2016. Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3:237-261.
  2. Li F. et al., 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 309:1864-1868.
  3. Walls A.C. et al., 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(2):281-292.e6.
  4. Wang N. et al., 2020. Subunit vaccines against emerging pathogenic human coronaviruses. Front. Microbiol. 11:298. DOI: 10.3389/fmicb.2020.00298.
  5. Padron-Regalado E., 2020. Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. Infect. Dis. Ther. DOI: 10.1007/s40121-020-00300-x.
  6. Monteil V.et al., 2020. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 181:1-9.


Datasheet Download


There are no reviews yet.

Be the first to review “2019-nCoV Spike RBD”

Your email address will not be published. Required fields are marked *